- Conditions
- Neoplasm
- Interventions
- preladenant, pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 5,453
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Interventions
- PF-08046049
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
- Conditions
- Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Interventions
- PT-112 Injection
- Drug
- Lead sponsor
- Promontory Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- gemcitabine hydrochloride, triapine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer
- Interventions
- LTZ-232
- Drug
- Lead sponsor
- LTZ Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
- Conditions
- Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 2,545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 175
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Duloxetine, Neurofeedback, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Interventions
- Motexafin Gadolinium Injection
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pancreatic Neoplasms
- Interventions
- KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Ewing Sarcoma, Ewing's Sarcoma Recurrent
- Interventions
- Palbociclib, Ganitumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
- Conditions
- Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
- Interventions
- Neratinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986299, Nivolumab, Ipilimumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- La Jolla, California • Orange, California • Sacramento, California + 6 more
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
- Interventions
- A166
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Interventions
- SF1126
- Drug
- Lead sponsor
- Semafore Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Atlanta, Georgia + 1 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tipifarnib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- G-202
- Drug
- Lead sponsor
- GenSpera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • San Antonio, Texas • Madison, Wisconsin
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- M1774, Niraparib
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more
- Conditions
- Solid Tumors
- Interventions
- EC D-3263 HCl
- Drug
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Interventions
- BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Drug
- Lead sponsor
- Bold Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Tampa, Florida
- Conditions
- Advanced Solid Tumor, Advanced Lymphoma
- Interventions
- SNX281, pembrolizumab
- Drug
- Lead sponsor
- Stingthera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 1 more
- Conditions
- Refractory Solid Tumors
- Interventions
- Eribulin, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- MEK162 + RAF265
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Portland, Oregon • Salt Lake City, Utah